Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 29:20:30.
doi: 10.1186/s12935-020-1117-2. eCollection 2020.

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

Giuseppe Nicolò Fanelli #  1 , Carlo Alberto Dal Pozzo #  1 , Ilaria Depetris #  2 , Marta Schirripa  2 , Stefano Brignola  1 , Paola Biason  2 , Mariangela Balistreri  1 , Luca Dal Santo  1 , Sara Lonardi  2 , Giada Munari  1   2 , Fotios Loupakis #  2 , Matteo Fassan #  1
Affiliations
Review

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

Giuseppe Nicolò Fanelli et al. Cancer Cell Int. .

Abstract

Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing one of the most frequent causes of cancer-related death worldwide. About 8-15% of CRCs harbor a mutation in BRAF gene, a proto-oncogene involved in cell proliferation, differentiation and survival through the MAPK signaling cascade. The acquisition of BRAF mutation is an early event in the "serrated" CRC carcinogenetic pathway and is associated with specific and aggressive clinico-pathological and molecular features. Despite that the presence of BRAF mutation is a well-recognized negative prognostic biomarker in metastatic CRC (mCRC), a great heterogeneity in survival outcome characterizes these patients, due to the complex, and still not completely fully elucidated, interactions between the clinical, genetic and epigenetic landscape of BRAF mutations. Because of the great aggressiveness of BRAF-mutated mCRCs, only 60% of patients can receive a second-line chemotherapy; so intensive combined and tailored first-line approach could be a potentially effective strategy, but to minimize the selective pressure of resistant clones and to reduce side effects, a better stratification of patients bearing BRAF mutations is needed.

Keywords: BRAF mutation; Colorectal cancer; Personalized medicine; Sequencing.

PubMed Disclaimer

Conflict of interest statement

Competing interestsFotios Loupakis had roles as a consultant or advisor for Roche, Bayer, Amgen and Genentech Pharmaceuticals. Sara Lonardi had roles as a consultant or advisor for Amgen, Bayer, Merck Serono and Lilly. She received research funding from Amgen and Merck Serono, and she is part of the speakers’ bureau of Lilly and BMS. Matteo Fassan had roles as a consultant or advisor for Tesaro and Astellas. He received research funding from Astellas and QED. The other authors have no competing interests to declare. The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Clinico-pathological features associated to BRAF-mutated colorectal cancers
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Smits AMM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–532. doi: 10.1056/NEJM198809013190901. - DOI - PubMed
    1. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi: 10.1038/nm.3967. - DOI - PMC - PubMed
    1. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the american society for clinical pathology, college of american pathologists, association for molecular pathology, and american society of clinical oncology. J Oncol Pract. 2017;13(5):333–337. doi: 10.1200/JOP.2017.022152. - DOI - PubMed
    1. Morkel M, Riemer P, Blaker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015;6:25. doi: 10.18632/oncotarget.4750. - DOI - PMC - PubMed